Blood
Articles in this Issue
LP-005, a bifunctional C5 antibody fusion protein, efficacy and safety in PNH patients with active hemolysis: Updated results from a Phase 2 study at 12/24 weeks
Abstract Background：Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematological disorder characterized by complement altern...
Analysis of real-world overall survival (rwOS) among patients with third-line or later (3L+) diffuse large B-cell lymphoma (DLBCL) with multiple qualifying index dates treated in the United States
Abstract Introduction: Standard of care (SOC) first line (1L) therapy for diffuse large B-cell lymphoma (DLBCL) includes rituximab, cyclopho...
Baseline characteristics, serological and measurable residual disease responses and outcomes in newly diagnosed multiple myeloma patients not planned for autologous stem cell transplant; Results from a prospective randomised study using MRD guided therapy
Abstract Introduction In recent times, Measurable Residual Disease(MRD) has emerged as a strong prognostic tool for Multiple Myeloma. It has...
A novel B7-H3-specific binder enables effective CAR T-cell therapy in an Acute Myeloid Leukemia experimental model
Abstract Background Acute myeloid leukemia (AML) is due to the clonal expansion of myeloid precursor cells driven by rec...
Immunological and transcriptomic analysis of febrile neutropenia in hematological malignancies: SOCS3/IL-6/NETs axis and NOD-like receptor signaling dysregulation
Abstract Objective: Chemotherapy-related febrile neutropenia (FN) is a high-risk complication in patients with hematolog...
Trends in overall survival in MDS from 2000–2022: Have therapeutic advances made a difference?
Abstract Introduction Myelodysplastic Syndrome (MDS) is a neoplastic clonal disorder of the hematopoietic stem cells, le...
Distinct blood endothelial cells shape spatial niches in angioimmunoblastic T-cell lymphoma
Abstract Background Angioimmunoblastic T cell lymphoma (AITL) is a subtype of peripheral T-cell lymphoma with a poor prognosis. Pathological...
Risk of postpartum hemorrhage in women with von willebrand disease by treatment type: An analysis of real-world data
Abstract Background: Women with von Willebrand disease (VWD) are at increased risk for postpartum hemorrhage (PPH), yet...
Efficacy of daratumumab in treatment of relapsed and/or refractory warm autoimmune hemolytic anemia in children
Abstract Introduction: Severe warm autoimmune hemolytic anemia (wAIHA) in children carries a high mortality rate. While steroids remain the...
Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study
Abstract Introduction: The primary analysis of the randomized Phase 3 S1826 study in patients (pts) with previously untreated, advanced stag...
Novel γδ T cell engager platform for cancer immunotherapy promoted T cell expansion with a persistence-indicating phenotype
Abstract Background: Gamma-delta (γδ) T cells initiate a broad, MHC-independent immune response to cancer, owing to their ability to overcom...
Real-world comparison of BTKi monotherapy and fixed-duration BTKi–Venetoclax for first line treatment of chronic lymphocytic leukemia patients without TP53 mutations or IGHV rearrangement
Abstract Background: Targeted regimens incorporating selective inhibitor of BCL-2 like venetoclax and Bruton Tyrosine Ki...
MagnetisMM-6 part 2: A phase 3, open-label, randomized study of elranatamab in combination with daratumumab and lenalidomide vs daratumumab, lenalidomide, and dexamethasone in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma
Abstract Background MagnetisMM-6 (NCT05623020) is an open-label, 2-arm, randomized, phase 3 study to evaluate the efficacy and safety of elr...
Single cell analysis of chronic myeloid leukemia bone marrow from time of TKI discontinuation reveals stem cell alterations associated with recurrence versus treatment free remission
Abstract Treatment free remission (TFR) is the ultimate goal for chronic myeloid leukemia (CML) patients, but only ~20% of all CML patients...
Polatuzumab vedotin induced activation of B-cell receptor signaling creates a synthetic lethality with BTK and AKT inhibition in Mantle Cell Lymphoma
Abstract Introduction. Polatuzumab Vedotin (PV) is an antibody-drug conjugate of anti-CD79B monoclonal antibody linked with monomethyl aurist...
Venetoclax-based therapy remodels T-cell and NK-cell immunity in patients with chronic lymphocytic leukemia
Abstract Introduction: Chronic lymphocytic leukemia (CLL) is characterized by profound immune dysregulations. Venetoclax (Ven), a selective...
BCR::ABL1/GUSB halving times predict molecular response to asciminib at 18 months
Abstract The initial rate of reduction of BCR::ABL1 mRNA on TKI therapy, usually measured as the halving time over the first 3 months of tre...
Real-world overall survival in patients with Acute Myeloid Leukemia treated with ivosidenib plus azacitidine in the USA: Trinetx-based analysis
Abstract Introduction In patients with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy, the combination of ivosidenib a...
Relationship between myeloma cell genomic alternations and tumor immune microenvironment in bone-related extramedullary disease of newly diagnosed multiple myeloma
Abstract Bone-related extramedullary disease (EMD-B) are a common extramedullary manifestation of multiple myeloma (MM), typically reflectin...
Identification of ferroptosis-sensitizers for DLBCL treatment
Abstract Diffuse large B-cell lymphoma (DLBCL) is the most common form of lymphoma in adults and represents a clinically and molecularly het...
Real-world outcomes of total body irradiation-based conditioning in allogeneic hematopoietic stem cell transplantation: A single-center retrospective study
Abstract Background Total body irradiation (TBI) is commonly used in conditioning regimens for allogeneic hematopoietic stem cell transplant...
Copeptin - a long-ignored peptide hormone
Abstract Arginine vasopressin (AVP), the antidiuretic hormone secreted by hypothalamic neurons, controls water resorption and blood pressure...
Synergistic cooperation between progranulin and Jak2/Stat3 signaling determines definitive myeloid cell fate
Abstract Perturbations in cell fate choices result in loss of tissue homeostasis and diseases like cancer and developmental disorders. A bet...
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in relapsed/refractory multiple myeloma: Results for patients aged < 75 years
Abstract The randomized phase III ADMYRE trial evaluated plitidepsin plus dexamethasone (DXM) versus DXM alone in patients with relapsed/ref...
Circulating endothelial extracellular vesicles from sickle cell patients promote susceptibility of pulmonary endothelium to thrombotic injury
Abstract Introduction: Sickle cell disease (SCD) is a genetic hemoglobinopathy characterized by recurrent vaso-occlusion, chronic hemolysis,...